Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (PEGASUS)
PEGASUS: PErsonalized Genomics for Prenatal Aneuploidy Screening USing Maternal Blood
Sponsor: CHU de Quebec-Universite Laval
This NA trial investigates Trisomy 13 and Trisomy 18 and is currently completed. CHU de Quebec-Universite Laval leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)The present study is a real life comparative effectiveness study that will compare the performances and costs of several prenatal screening modalities for fetal aneuploidy (see interventions).
The present study is a real life comparative effectiveness study that will compare the performances and costs of several prenatal screening modalities for fetal aneuploidy (see interventions).
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Completed NA
-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Mar 2018 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jul 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CHU de Quebec-Universite Laval
- Canadian Institutes of Health Research (CIHR)
- Genome British Columbia
- Genome Canada
- Genome Quebec
- Laval University
For direct contact, visit the study record on ClinicalTrials.gov .